Analyst Ratings For NASDAQ:NEO – NeoGenomics (NASDAQ:NEO)
Today, NASDAQ:NEO – NeoGenomics (NASDAQ:NEO) stock received an upgrade by BTIG Research from Neutral to Buy.
Some recent analyst ratings include
- 4/16/2018-BTIG Research Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 10/26/2017-Janney Montgomery Scott Reiterated Rating of Buy.
- 8/24/2017-Gabelli initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:NEO – NeoGenomics (NASDAQ:NEO)
NASDAQ:NEO – NeoGenomics (NASDAQ:NEO) has insider ownership of 11.20% and institutional ownership of 84.63%.
- On 7/27/2017 Alison L Hannah, Director, bought 20,000 with an average share price of $9.19 per share and the total transaction amounting to $183,800.00.
- On 6/22/2017 Jennifer Balliet, VP, sold 10,723 with an average share price of $8.49 per share and the total transaction amounting to $91,038.27.
- On 6/5/2017 Steven A Ross, Insider, sold 70,833 with an average share price of $7.76 per share and the total transaction amounting to $549,664.08.
- On 5/26/2017 Jennifer Balliet, VP, sold 3,334 with an average share price of $7.50 per share and the total transaction amounting to $25,005.00.
- On 3/20/2017 Steven G Brodie, Insider, sold 50,000 with an average share price of $7.93 per share and the total transaction amounting to $396,500.00.
- On 9/23/2016 Maher Albitar, Insider, sold 2,800 with an average share price of $8.40 per share and the total transaction amounting to $23,520.00.
- On 9/20/2016 Maher Albitar, Insider, sold 105,300 with an average share price of $8.20 per share and the total transaction amounting to $863,460.00.
Recent Trading Activity for NASDAQ:NEO – NeoGenomics (NASDAQ:NEO)
Shares of NASDAQ:NEO – NeoGenomics closed the previous trading session at 8.98 up +0.49 5.77% with 57462 shares trading hands.